The Case for Early Adoption of mNGS Pathogen Detection

In this LinkedIn Live session, Dr. Kyle Rodino of Penn Medicine presents compelling evidence on how early adoption of Delve Bio’s metagenomic next-generation sequencing (mNGS) for cerebrospinal fluid (CSF) can improve patient care guided through diagnostic stewardship. Through real-world case studies, he demonstrates that implementing mNGS in the diagnostic workflow can accelerate the detection of complex pathogens, reduce unnecessary testing, and shorten hospital stays for critically ill patients.